Sponsored
Page 1/3

Intercell

Valneva Completes EUR 45 Million Capital Increase

The listed biotechnology company Valneva SE announces the completion of its capital increase with shareholders preferential subscription rights launched on January 12th, 2015. Valneva estimates net proceeds of EUR 42 millions from 18.2 million offered new shares. The new ordinary shares will be traded on Euronext and on the Prime Market segment of the Vienna Stock Exchange. The financing will mainly be used for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral.

February 4, 2015

Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S.

Intercell Announces Pediatric Approval of its Japanese Encephalitis Vaccine in the U.S.

May 21, 2013

Intercell AG / Merger between Intercell and Vivalis planned to complete on May 28, 2013 - Relevant documents filed with the Commercial Court of Lyon

Intercell AG / Merger between Intercell and Vivalis planned to complete on May 28, 2013 - Relevant documents filed with the Commercial Court of Lyon

May 14, 2013

Intercell AG / Yearly Report

Intercell AG / Yearly Report

April 23, 2013

Intercell AG / Vivalis SA shareholders approved the proposed merger of equals to create Valneva SE

Intercell AG / Vivalis SA shareholders approved the proposed merger of equals to create Valneva SE

March 7, 2013

Intercell AG announces Q4 and preliminary full year 2012 financial results and business update

Intercell AG announces Q4 and preliminary full year 2012 financial results and business update

March 5, 2013

Intercell AG / Intercell announces pediatric approval of its Japanese Encephalitis vaccine in Europe

Intercell AG / Intercell announces pediatric approval of its Japanese Encephalitis vaccine in Europe

February 12, 2013

Intercell AG / Intercell and Vivalis provide update on the progress towards intended merger

Intercell AG / Intercell and Vivalis provide update on the progress towards intended merger

January 28, 2013

Intercell receives CHMP positive opinion for the pediatric indication of its Japanese Encephalitis vaccine in Europe

Intercell receives CHMP positive opinion for the pediatric indication of its Japanese Encephalitis vaccine in Europe

December 19, 2012

Intercell AG announces Q3 2012 financial results and provides operational update

Intercell AG announces Q3 2012 financial results and provides operational update

November 7, 2012

Intercell AG provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance

Intercell AG provides update on IXIARO®/JESPECT® sales growth and expected full year financial performance

October 16, 2012

Vienna Stock Exchange: Winners and Losers (2012-06-02)

Daily News Flash from the Vienna Stock Exchange: Upgrades and Downgrades, Analyzes and Comments.

June 2, 2012

Intercell Completes Equity Private Placement

The Austrian pharmaceutical company raises funds of € 15.2m at a price of € 2.30 per new share - bringing total volume of combined debt and equity financing to € 35.2m.

May 15, 2012

Intercell Remains in the Loss Area

The Austrian pharmaceutical company recorded a net loss of € 8.1m in the first quarter of 2012 after € 11.3m in the first quarter of 2011.

May 8, 2012

Vienna Stock Exchange: Winners and Losers (2012-05-07)

Daily News-Flash from Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.

May 7, 2012 · Updated: May 7, 2012; 18:33

Vienna Stock Exchange: Winners and Losers (2012-04-27)

Daily News-Flash from Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.

April 27, 2012

Vienna Stock Exchange: Winners and Losers (2012-03-07)

Daily News Flash from Vienna Stock Exchange. Upgrades and Downgrades, Winners and Losers.

March 7, 2012 · Updated: March 7, 2012; 19:41

Intercell Does Not Leave the Loss zone

The Austrian pharmaceutical company announces preliminary full year 2011 financial results. Losses totaled € 29m.

March 6, 2012

Vienna Stock Exchange: Winners and Losers (2012-02-25)

Daily News-Flash from Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.

February 25, 2012

Intercell Plans to Achieve Turnaround in 2014

The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.

February 6, 2012

Vienna Stock Exchange: Winners and Losers (2012-01-18)

Daily News-Flash from the Vienna Stock Exchange: Upgrades and Downgrades, Winners & Losers.

January 18, 2012 · Updated: January 18, 2012; 17:58

Vienna Stock Exchange: Winners and Losers (2012-01-16)

Daily News-Flash from Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.

January 16, 2012

New Chairman for Intercell’s Supervisory Board

Thomas Szucs succeeds Michael Gréco who remains on the Supervisory Board of the Austrian pharmaceutical company.

December 30, 2011

Vienna Stock Exchange: Winners and Losers (2011-12-10)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

December 10, 2011

Vienna Stock Exchange: Winners and Losers (2011-12-09)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

December 9, 2011 · Updated: December 9, 2011; 18:00

Vienna Stock Exchange: Winners and Losers (2011-12-08)

Daily News-Flash from the Vienna Stock Exchange. Upgrades & Downgrades, Winners & Losers.

December 8, 2011

Vienna Stock Exchange: Winners and Losers (2011-11-16)

Daily News-Flash from the Vienna Stock Exchange. Upgrades & Downgrades, Winners & Losers.

November 16, 2011

Intercell Receives Approval for Vaccine in India

The Austrian pharmaceutical company achieved an important milestone in the roll-out of its Japanese Encephalitis vaccine in endemic countries.

November 10, 2011

Intercell Still Reports Losses

The Austrian pharmaceutical company could reduce its net losses from € 50.8m to € 20.62m. For the full year the net loss expectations ranges up to € 40m.

November 8, 2011

Vienna Stock Exchange: Winners and Losers (2011-11-02)

Daily News-Flash from the Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.

November 2, 2011

R&D Expenses on the Rise

The largest Austrian Enterprises increased their budgets for research & development by 9.6% on average. This is slightly beyond the global average (9.3%).

October 24, 2011

Intercell Continues Development of Vaccines

The Austrian pharmaceutical company announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections.

October 24, 2011

29 Austrian Companies Ranked in "EU Industrial R&D Investment Scoreboard"

Benteler International, Voestalpine, Borealis, Intercell, Zumtobel are the first five Austrian firms in the “EU Industrial R&D Investment Scoreboard”. The ranking was prepared by the European Commission.

October 19, 2011

Intercell: EU Invests € 30m in Research Program

The Austrian pharmaceutical company will receive co-funding for a collaborative research project from the European Union.

September 29, 2011

Intercell Looking for Private Equity Shareholder

According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.

September 27, 2011

Intercell Successfully Completes Vaccine Study in India

The Austrian biotech company achieved an important step in the licensure process of a vaccine for children.

September 16, 2011

Vienna Stock Exchange: Winners and Losers (2011-09-07)

Daily News-Flash from the Vienna Stock Exchange: Upgrades and Downgrades, Winners and Losers.

September 7, 2011

Vienna Stock Exchange: Winners and Losers (2011-08-18)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

August 18, 2011

Intercell: Restructuring Is Progressing

Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.

August 16, 2011

Intercell Is Looking for Financial Investors

The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.

July 19, 2011

Vienna Stock Exchange: Winners and Losers (2011-06-30)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

June 30, 2011

Vienna Stock Exchange: Winners and Losers (2011-06-24)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

June 24, 2011

Intercell: “We Will Stabilize Our Share Price”

The Austrian biotech company recorded a dramatic drop in its share price. The CEO remains optimistic and promises stabilization.

June 21, 2011

Vienna Stock Exchange: Winners and Losers (2011-06-15)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

June 15, 2011

Vienna Stock Exchange: Winners and Losers (2011-06-14)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

June 14, 2011

Vienna Stock Exchange: Winners and Losers (2011-06-10)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

June 10, 2011

Vienna Stock Exchange: Winners and Losers (2011-06-09)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

June 9, 2011

Vienna Stock Exchange: Winners and Losers (2011-06-08)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

June 8, 2011

Intercell to Cut Jobs and Research Budget

The share price plunged by more than 30% after the Austrian pharmaceutical company had announced the termination of a vaccine study.

June 8, 2011

Vienna Stock Exchange: Winners and Losers (2011-05-23)

Daily News-Flash from the Vienna Stock Exchange: Upgrades & Downgrades, Winners & Losers.

May 23, 2011